Want to see WST full AI Analyst Report?
WST Stock Chart & Stats
$273.73
$0.15(0.05%)
At close: 4:00 PM EST
$273.73
$0.15(0.05%)
Day’s Range― - ―
52-Week Range$206.80 - $367.66
Previous CloseN/A
Volume102.64K
Average Volume (3M)771.21K
Market Cap
$24.99B
Enterprise Value$22.66B
Total Cash (Recent Filing)$521.40M
Total Debt (Recent Filing)$316.20M
Price to Earnings (P/E)47.6
Beta0.78
Next Earnings
Jul 23, 2026EPS Estimate
2.08Next Dividend Ex-DateN/A
Dividend Yield0.32%
Share Statistics
EPS (TTM)7.52
Shares Outstanding70,647,600
10 Day Avg. Volume822,369
30 Day Avg. Volume771,211
Financial Highlights & Ratios
PEG Ratio33.99
Price to Book (P/B)6.26
Price to Sales (P/S)6.47
P/FCF Ratio42.42
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue7.04
Enterprise Value/Gross Profit19.41
Enterprise Value/Ebitda26.86
Forecast
1Y Price Target
$386.43Price Target Upside41.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)8.61
Revenue Forecast (FY)$3.33B
Bulls Say, Bears Say
Bulls Say
High-Value Products (HVP) & GLP-1 ExposureA large, fast-growing HVP mix anchored by GLP-1 exposure provides durable structural demand as manufacturers scale injectable biologics. High-value components command premium pricing and multi-year qualification cycles, creating recurring revenue, favorable mix, and margin resilience as product lifecycles persist.
Conservative Balance SheetVery low leverage and a sizable equity base grant long-term financial flexibility to fund capacity, M&A, or buybacks without stressing liquidity. This conservative capital structure reduces refinancing risk, supports investment through cycles, and underpins sustained operational execution.
Solid Cash Generation And Margin ExpansionConsistent operating cash flow and meaningful free cash flow, coupled with recent margin expansion, support reinvestment, R&D, and shareholder returns. Strong cash conversion and improving margins reflect mix shift to HVP and operational leverage that should sustain profitability over the medium term.
Bears Say
Back-half CGM Contract Roll-offA confirmed contract loss creates a persistent revenue gap in H2 that reduces visibility and adds pressure to replace volumes. While manageable relative to total sales, the roll-off highlights customer concentration and the need to convert new wins to offset lost, contracted revenue streams.
Slow Site Qualification TimelinesLengthy 6–12 month qualification lead times constrain the firm's ability to rapidly shift or add capacity to meet sudden demand surges. Structural lag in scaling multi-site supply introduces execution risk for customers and limits responsiveness to fast-growing therapy launches.
Ramp-Related Margin Variability (West Vantage & SmartDose)New-site ramping and transaction timing can depress segment margins and introduce quarter-to-quarter variability. Persistent ramp costs or slower efficiency gains at contract-manufacturing sites could weigh on consolidated margins and delay the realization of expected operating leverage.
West Pharmaceutical Services News
WST FAQ
What was West Pharmaceutical Services, Inc.’s price range in the past 12 months?
West Pharmaceutical Services, Inc. lowest stock price was $206.80 and its highest was $367.66 in the past 12 months.
What is West Pharmaceutical Services, Inc.’s market cap?
West Pharmaceutical Services, Inc.’s market cap is $24.99B.
When is West Pharmaceutical Services, Inc.’s upcoming earnings report date?
West Pharmaceutical Services, Inc.’s upcoming earnings report date is Jul 23, 2026 which is in 13 days.
How were West Pharmaceutical Services, Inc.’s earnings last quarter?
West Pharmaceutical Services, Inc. released its earnings results on Apr 23, 2026. The company reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.678 by $0.452.
Is West Pharmaceutical Services, Inc. overvalued?
According to Wall Street analysts West Pharmaceutical Services, Inc.’s price is currently Undervalued.
Does West Pharmaceutical Services, Inc. pay dividends?
West Pharmaceutical Services, Inc. pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 0.32%. See more information on West Pharmaceutical Services, Inc. dividends here
What is West Pharmaceutical Services, Inc.’s EPS estimate?
West Pharmaceutical Services, Inc.’s EPS estimate is 2.08.
How many shares outstanding does West Pharmaceutical Services, Inc. have?
West Pharmaceutical Services, Inc. has 70,647,600 shares outstanding.
What happened to West Pharmaceutical Services, Inc.’s price movement after its last earnings report?
West Pharmaceutical Services, Inc. reported an EPS of $2.13 in its last earnings report, beating expectations of $1.678. Following the earnings report the stock price went up 12.86%.
Which hedge fund is a major shareholder of West Pharmaceutical Services, Inc.?
Currently, no hedge funds are holding shares in WST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
West Pharmaceutical Services Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$386.43 (41.17% Upside)
$386.43 (41.17% Upside)
Blogger Sentiment
Bullish
WST Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 925.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 8.5%
Last 30 Days ▲ 8.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.94%
12-Months-Change
Fundamentals
Return on Equity
17.87%
Trailing 12-Months
Asset Growth
13.59%
Trailing 12-Months
Company Description
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
WST Company Deck
WST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported broad-based, above-expectation Q1 results with strong revenue growth, substantial margin expansion and raised full-year guidance. Key growth engines—HVP components (including GLP-1s), biologics/NovaPure, Annex 1 conversions, and delivery devices—showed robust performance and underpin optimism. Near-term headwinds include a ~$40M CGM contract roll-off in H2, AR-driven cash flow timing effects, ramp-related margin variability and some commodity cost pressure, but management has mitigation plans and a strong balance sheet (including a new $1B buyback). Overall, positive operational execution and upgraded guidance outweigh the manageable challenges.View all WST earnings summariesWST Revenue Breakdown
81.07% Proprietary Products
18.93% Contract-Manufactured Products
0.00% Intersegment sales elimination
WST Stock 12 Month Forecast
Average Price Target
$386.43
▲(41.17% Upside)
Technical Analysis
Ownership Overview
0.55% Insiders
26.42% Mutual Funds
0.39% Other Institutional Investors
41.74% Public Companies and
Individual Investors